

# Novel Deep Learning Model for the Detection of Cardiac Amyloidosis: A Pilot Reader Study

Jeremy A. Slivnick<sup>1</sup>, Ashley Ackerman<sup>2</sup>, Jorge Oliveira<sup>2</sup>, Will Hawkes<sup>2</sup>, Agis Chartsias<sup>2</sup>, Ross Upton<sup>2</sup>, Federico M. Asch<sup>3</sup>, Juan I. Cotella<sup>1</sup>, Linda Lee<sup>1</sup>, Giancarlo Saldana<sup>1</sup>, Christopher Fernandez<sup>1</sup>, Jia Guo<sup>1</sup>, Karima Addetia<sup>1</sup>, Matthew Maurer<sup>4</sup>, Steven Helmke<sup>4</sup>, Vidhushei Yogeswaran<sup>5</sup>, Richard Cheng<sup>5</sup>, James N. Kirkpatrick<sup>5</sup>, Karolina Zareba<sup>6</sup>, Masaaki Takeuchi<sup>7</sup>, Tetsuji Kitano<sup>7</sup>, Marcelo Luz<sup>8</sup>, Viviane Hotta<sup>8</sup>, Aldo Prado<sup>9</sup>, Pablo Ellisamburu<sup>10</sup>, Marielle Scherrer-Crosbie<sup>11</sup>, Marwa Soltani<sup>11</sup>, Akhil Narang<sup>12</sup>, Gary Woodward<sup>2</sup>, Roberto M. Lang<sup>1</sup>


<sup>1</sup>University of Chicago, Chicago IL; <sup>2</sup>Ultromics Ltd., Oxford, UK; <sup>3</sup>MedStar Health, Washington DC; <sup>4</sup>Columbia University, New York NY; <sup>5</sup>University of Washington, Seattle WA; <sup>6</sup>Ohio State University, Columbus, OH; <sup>7</sup>University of Occupational and Environmental Health, Kitakyushu, Japan; <sup>8</sup>INCOR, São Paulo, Brazil; <sup>9</sup>Instituto Privado Tucuman, Tucuman, Argentina; <sup>10</sup>ICBA, Buenos Aires, Argentina; <sup>11</sup>University of Pennsylvania, Philadelphia PA; <sup>12</sup>Northwestern University, Chicago IL

## Background

- While TTE remains the frontline imaging modality for patients with cardiac amyloidosis (CA), classical TTE findings often lack sensitivity, resulting in delayed diagnosis and treatment.
- The aim of this study was to develop a deep learning (DL) model to detect CA and perform a preliminary assessment of its capabilities to assist readers.

## Methods

- We trained and validated (75%/25% split) a 3D convolutional neural network to detect CA using 2757 apical 4-chamber (A4C) images derived from confirmed CA patients and controls.
- Utilizing a separate test dataset of 60 CA (30 AL, 30 ATTR) and 60 clinically relevant controls (Figure 1A), we performed a pilot study to assess the accuracy of 2 expert and 3 non-expert readers for the detection of CA using only A4C images.
- Readers assessed all images in a fully-crossed design (Figure 1A) with and without the aid of the DL model output.
- The reads consisted of binary interpretations indicating presence or absence of CA and high/low confidence in the interpretation.
- Accuracy, sensitivity, and specificity were compared between aided and non-aided reads for statistical difference (paired t-test) and statistical equivalence (two paired one-sided t-tests).



**Figure 1.** (A) Schematic of reader study design; (B) ROC curves for DL model, aided, and unaided readers in the test cohort. Comparison of reader (C) overall accuracy and (D) proportion of studies in which readers provided a confident interpretation for detection of CA with and without the aid of the DL model.

## Results

- The DL model demonstrated an accuracy, sensitivity and specificity in the test dataset of 85% (95% CI: 81.6%, 88.2%), 88.3% (95% CI: 84.1, 92.3%), and 81.7% (95% CI 76.6, 80.3%), respectively (Figures 1B/1C).
- Aided by the DL model, readers demonstrated the potential for small improvements in performance (Figure 1C/1D), with the suggestion of larger benefits to be observed in non-experts.
- However, comparisons between aided and unaided reads were not significantly different, nor statistically equivalent, for any performance metric (all  $p \geq 0.176$ ).

## Conclusions

- In this multicenter, multi-vendor study, we developed a novel DL model which demonstrated excellent performance for differentiating CA from clinically relevant controls.
- Although the study demonstrates the potential for DL model to improve reader accuracy, particularly in non-experts, our findings indicate the need for a larger reader study to better understand if DL can augment clinical decision making to promote earlier CA diagnosis and treatment.

Disclosures: Several co-authors are employees of Ultromics Ltd.

